IMV Inc.
IMV.TO
Toronto Stock Exchange1.12
CAD
- -
- -
IMV Inc.
IMV.TO
(Toronto Stock Exchange)
Recent
price
1.12
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- IMV Inc. IMV Inc. (TSX: IMV) operates as a clinical-stage biopharmaceutical company focused on immuno-oncology therapies and vaccines against infectious diseases. The company develops a portfolio of therapies based on its proprietary DPX immune-educating technology platform, which programs immune cells in vivo to target survivin-expressing cancer cells and generate specific anti-tumor responses; its lead candidate, maveropepimut-S (MVP-S), advances in Phase II trials for diffuse large B-cell lymphoma and platinum-resistant ovarian cancer, Phase I for breast cancer, and additional evaluations in bladder, liver, and MSI-H solid tumors. IMV offers DPX-based immunotherapies for solid and hematological cancers, as well as vaccine platforms addressing infectious diseases including COVID-19, with applications in antigen desensitization and autoimmune conditions. Founded in 2007 and headquartered in Dartmouth, Nova Scotia, Canada, the company targets global markets in oncology and immunology, primarily through clinical partnerships and collaborations in North America and Europe. In a major strategic shift, BioVaxys Technology Corp. acquired IMV's full portfolio of discovery, preclinical, and clinical-stage assets, including the DPX platform and maveropepimut-S, in February 2024 for US$750,000 cash and over 5 million shares, with a formal amendment executed with Horizon Technology Finance Corp. in September 2025 to solidify the transaction; this divestiture followed financial challenges, enabling continued development under BioVaxys while IMV shares trade on the TSX post-restructuring.